1 Berman RM, Narasimhan M, Charney DS. Treatment-refractory depression: Definitions and characteristics. Depress Anxiety. 1997;5(4):154–64.
2 Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627–47.
3 Angst J. The course of affective disorders. Psychopathology. 1986;19 Suppl 2:47–52.
4 Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr. 1995;146(1):5–16.
5 Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49(10):809–16.
6 Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry. 2002;181(3):208–13.
7 Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23.
8 Kronenberg G, Desai D, Anghelescu I. When two drugs are not better than one: Treating mood symptoms in patients with chronic opioid use. J Affect Disord. 2019;259:173–4.
9 Landolt S, Rosemann T, Blozik E, Brüngger B, Huber CA. Benzodiazepine and z-drug use in Switzerland: Prevalence, prescription patterns and association with adverse healthcare outcomes. Neuropsychiatr Dis Treat. 2021;17:1021–34.
10 Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: Tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29(4):127–34.
11 Wertli MM, Held U, Signorell A, Steurer J, Blozik E, Burgstaller JM. Opioid prescription in Switzerland: Appropriate comedication use in Cancer and noncancer pain. Pain Physician. 2019;22(6):537–48.
12 Parker GB, Graham RK. Determinants of treatment-resistant depression: The salience of benzodiazepines. J Nerv Ment Dis. 2015;203(9):659–63.
13 Pompili M, Venturini P, Palermo M, Stefani H, Seretti ME, Lamis DA, et al. Mood disorders medications: Predictors of nonadherence – review of the current literature. Expert Rev Neurother. 2013;13(7):809–25.
14 Chong WW, Aslani P, Chen TF. Effectiveness of interventions to improve antidepressant medication adherence: A systematic review. Int J Clin Pract. 2011;65(9):954–75.
15 Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):e1.
16 Dold M, Bartova L, Rupprecht R, Kasper S. Dose escalation of antidepressants in unipolar depression: A meta-Analysis of double-blind, randomized controlled trials. Psychother Psychosom. 2017;86(5):283–91.
17 Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand. 1997;95(4):288–96.
18 Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25(1):71–9.
19 Fava M, Rosenbaum JF, Cohen L, Reiter S, McCarthy M, Steingard R, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord. 1992;25(4):229–34.
20 Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl). 2002;161(2):143–51.
21 Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry. 1990;51(1):8–11.
22 Schweizer E, Rynn M, Mandos LA, Demartinis N, García-España F, Rickels K. The antidepressant effect of sertraline is not enhanced by dose titration: Results from an outpatient clinical trial. Int Clin Psychopharmacol. 2001;16(3):137–43.
23 Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601–9.
24 Burchi E, Fava M. Optimal dosing of antidepressant drugs. Lancet Psychiatry. 2019;6(10):805–6.
25 Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: Influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos. 2005;33(11):1679–87.
26 Jacques RM, Cox SJ. Verapamil in major (psychotic) depression. Br J Psychiatry. 1991;158(1):124–5.
27 Pollack MH, Rosenbaum JF. Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry. 1987;22(6):779–82.
28 Breitenstein B, Scheuer S, Brückl TM, Meyer J, Ising M, Uhr M, et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res. 2016 Feb;73:86–95.
29 Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203–9.
30 O’Brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol. 2013;16(10):2259–72.
31 Kasper S. Is treatment-resistant depression really resistant? Eur Neuropsychopharmacol. 2022;58:44–6.
32 Dudek D, Rybakowski JK, Siwek M, Pawłowski T, Lojko D, Roczeń R, et al. Risk factors of treatment resistance in major depression: Association with bipolarity. J Affect Disord. 2010;126(1-2):268–71.
33 Sagud M, Mihaljevic-Peles A, Uzun S, Cusa BV, Kozumplik O, Kudlek-Mikulic S, et al. The lack of association between components of metabolic syndrome and treatment resistance in depression. Psychopharmacology (Berl). 2013;230(1):15–21.
34 Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al.; Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.
35 Huang SS, Chen HH, Wang J, Chen WJ, Chen HC, Kuo PH. Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study. BMC Psychiatry. 2020;20(1):541.
36 Malhi GS, Parker GB, Crawford J, Wilhelm K, Mitchell PB. Treatment-resistant depression: Resistant to definition? Acta Psychiatr Scand. 2005;112(4):302–9.
37 Kautzky A, Dold M, Bartova L, Spies M, Kranz GS, Souery D, et al. Clinical factors predicting treatment resistant depression: Affirmative results from the European multicenter study. Acta Psychiatr Scand. 2019;139(1):78–88.
38 McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. The identification, assessment and management of difficult-to-treat depression: An international consensus statement. J Affect Disord. 2020;267:264–82.
39 Dold M, Kasper S. Dose-response relationship of selective serotonin reuptake inhibitors. Acta Psychiatr Scand. 2020;142(6):427–9.
40 Bauer M, Severus E, Möller HJ, Young AH; WFSBP Task Force on Unipolar Depressive Disorders. Pharmacological treatment of unipolar depressive disorders: Summary of WFSBP guidelines. Int J Psychiatry Clin Pract. 2017;21(3):166–76.
41 Diekamp B, Borentain S, Fu DJ, Murray R, Heerlein K, Zhang Q, et al. Effect of concomitant benzodiazepine use on efficacy and safety of esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior: Pooled randomized, controlled trials. Neuropsychiatr Dis Treat. 2021;17:2347–57.
42 Andrashko V, Novak T, Brunovsky M, Klirova M, Sos P, Horacek J. The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Front Psychiatry. 2020;11:844.
43 Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: Implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–6.
44 Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921–7.
45 Casey MF, Perera DN, Clarke DM. Psychosocial treatment approaches to difficult-to-treat depression. Med J Aust. 2013;199 S6:S52–5.
46 Degerlund Maldi K, Asellus P, Myléus A, Norström F. Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression. BMC Psychiatry. 2021;21(1):610.
47 Heijnen WT, Birkenhäger TK, Wierdsma AI, van den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: A meta-analysis. J Clin Psychopharmacol. 2010;30(5):616–9.
48 Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. Transl Psychiatry. 2021;11(1):330.
49 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, Version 3.0. 2022 [cited 2023 Jan 06]. DOI: 10.6101/AZQ/000493. https://www.leitlinien.de/themen/depression
50 Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: Asystematic review and network meta-analysis. Curr Med Res Opin. 2017;33(4):701–11.
51 Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, et al. Augmentation therapies for treatment-resistant depression: Aystematic review and meta-analysis. Br J Psychiatry. 2019;214(1):42–51.
52 Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.
53 Colla M, Scheerer S, Weidt S, Seifritz E, Kronenberg G. Novel insights into the neurobiology of the antidepressant response from ketamine research: A mini review. Front Behav Neurosci. Epub 2021 Dec 3.
54 Corssen G, Domino EF. Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg. 1966;45(1):29–40.
55 Corssen G, Gutierrez J, Reves JG, Huber FC Jr. Ketamine in the anesthetic management of asthmatic patients. Anesth Analg. 1972;51(4):588–96.
56 Schweizerisches Heilmittelinstitut [Internet]. ORT: Swissmedic. Swiss Public Assessment Report Spravato. c2020 [cited 2023 Jan 06]. Available from: https://www.swissmedic.ch/swissmedic/de/home/suche.html#Spravato.
57 Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2018;75(2):139–48.
58 Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–38.
59 Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616–30.
60 Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903.
61 Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: A phase 2b randomized clinical study. BMC Psychiatry. 2021;21(1):526.
62 Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542–55.
63 Albott CS, Shiroma PR, Cullen KR, Johns B, Thuras P, Wels J, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78(3):e308–9.
64 Roxas N, Ahuja C, Isom J, Wilkinson ST, Capurso N. A potential case of acute ketamine withdrawal: Clinical implications for the treatment of refractory depression. Am J Psychiatry. 2021;178(7):588–91.
65 Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, et al. Intravenous arketamine for treatment-resistant depression: Open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271(3):577–82.
66 Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632.
67 Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:5–9.
68 Solomon DA, Keller MB, Leon AC, Mueller TI, Shea MT, Warshaw M, et al. Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry. 1997;54(11):1001–6.